Development and characterization of a new oral dapsone nanoemulsion system: Permeability and in silico bioavailability studies

International Journal of Nanomedicine

Volumn 7, Issue , 2012, Pages 5175-5182

  Monteiro, Lidiane M ^a   Lione, Viviane F ^a   do Carmo, Flavia A ^a   do Amaral, Lilian H ^a   da Silva, Julianna H ^a   Nasciutti, Luiz E ^a   Rodrigues, Carlos R ^a   Castro, Helena C ^b   de Sousa, Valeria P ^a   Cabral, Lucio M ^a  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b FLUMINENSE FEDERAL UNIVERSITY   (Brazil)

Author keywords

Antibacterial; Caco 2 cell; Dapsone; Gastroplus ; Nanoemulsions; Permeability

Indexed keywords

DAPSONE; PACLITAXEL; SURFACTANT;

AREA UNDER THE CURVE; ARTICLE; COMPUTER MODEL; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG PENETRATION; DRUG POTENCY; DRUG RELEASE; DRUG SOLUBILITY; DRUG STABILITY; HUMAN; HUMAN CELL; IN VIVO STUDY; LIPOPHILICITY; MAXIMUM PLASMA CONCENTRATION; NANOEMULSION; STOMACH JUICE; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADMINISTRATION, ORAL; ANTI-INFECTIVE AGENTS; BIOLOGICAL AVAILABILITY; CACO-2 CELLS; COMPUTER SIMULATION; DAPSONE; DIFFUSION; EMULSIONS; HUMANS; MODELS, BIOLOGICAL; MODELS, CHEMICAL; NANOCAPSULES; PARTICLE SIZE; PERMEABILITY;

MYCOBACTERIUM LEPRAE;

EID: 84870330674     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S36479     Document Type: Article

References (36)

1. Legendre DP, Muzny CA, Swiatlo E. Hansen's disease (leprosy): current and future pharmacotherapy and treatment of disease-related immunologic reactions. Pharmacotherapy. 2012;32:27-37.
2. Dhople AM. In vitro activity of epiroprim, a dihydrofolate reductase inhibitor, singly and in combination with brodimoprim and dapsone, against Mycobacterium leprae. Int J Antimicrob Agents. 1999;12:319-323.
3. Zhu YI, Stiller MJ. Dapsone and sulfones in dermatology: overview and update. J Am Acad Dermatol. 2001;45:420-434.
4. Wozel VE. Innovative use of dapsone. Dermatol Clin. 2010;28: 599-610.
5. Lindenberg M, Kopp S, Dressman JB. Classification of orally administered drugs on the World Health Organization model list of essential medicines according to the Biopharmaceutics classification system. Eur J Pharm Biopharm. 2004;58:265-278.
6. Yuan Y, Li S, Mo F, Zhong D. Investigation of microemulsion system for transdermal delivery of meloxicam. Int J Pharm. 2006;321: 117-123.
7. Jain J, Fernandes C, Patravale V. Formulation development of parenteral phospholipid-based microemulsion of etoposide. AAPS Pharm Sci Tech. 2010;11:826-831.
8. Nandi I, Bari M, Joshi H. Study of isopropyl myristate microemulsion systems containing cyclodextrins to improve the solubility of two model hydrophobic drugs. AAPS Pharma Sci Tech. 2003;4:E10.
9. Nornoo AO, Zheng H, Lopes LB, Restrepo BJ, Kannan K, Reed R. Oral microemulsions of paclitaxel: in situ and pharmacokinetic studies. Eur J Pharm Biopharm. 2009;71:310-317.
10. Moulik SP, Paul BK. Structure, dynamics and transport properties of microemulsions. Adv Colloid Interface Sci. 1998;78:99-195.
11. Lawrence MJ, Rees GD. Microemulsion-based media as novel drug delivery systems. Adv Drug Deliv Rev. 2000;45:89-121.
12. International Conference on Harmonization. Q1A(R2). Stability testing of new drug substance and products. US Food and Drug Administration Federal Register, 2003. Available from: http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q1A_R2/Step4/Q1A_R2__Guideline.pdf. Accessed October 4, 2011.
13. Queiroz RHC, Dreossi SA, Carvalho DJ. Potentiation the effect methemoglobinemia dapsone in rats by N-acetylcysteine. J Anal Toxicol. 1997;21:203-207.
14. US Pharmacopeia. NF-28 1092. The Dissolution Procedure: Development and Validation. 33th ed. Rockville, MD: US Pharmacopeia; 2010.
15. Costa P, Lobo JMS. Modeling and comparison of dissolution profiles. Eur J Pharm Sci. 2001;12:123-133.
16. Biganzoli E, Cavenaghi AL, Rossi R, Brunati CM, Nolli LM. Use of a Caco-2 cell culture model for the characterization of intestinal absorption of antibiotics. Il Farmaco. 1999;54:594-599.
17. Calatayud M, Gimeno J, Vélez D, Devesa V, Montoro R. Characterization of the intestinal absorption of arsenate, monomethylarsonic acid, and dimethylarsinic acid using the Caco-2 cell line. Chem Res Toxicol. 2010;23:547-556.
18. Sandri G, Bonferoni MC, Rossi S, Ferrari F, Boselli C, Caramella C. Insulin-loaded nanoparticles based on n-trimethyl chitosan: in vitro (Caco-2model) and ex vivo (excised rat jejunum, duodenum, and ileum) evaluation of penetration enhancement properties. AAPS Pharma Sci Tech. 2010;11:362-371.
19. Markowska M, Oberle R, Juzwin S, Hsu CP, Gryszkiewicz M, Streeter AJ. Optimizing Caco-2 cell monolayers to increase throughput in drug intestinal absorption analysis. J Pharmacol Toxicol Methods. 2001;46:51-55.
20. Ranaldi G, Islam K, Sambuy Y. Epithelial cells in culture as a model for the intestinal transport of antimicrobial agents. Antimicrob Agents Chemother. 1992;36:1374-1381.
21. Grbic S, Parojcic J, Ibric S, Djuric Z. In vitro-in vivo correlation for gliclazide immediate-release tablets based on mechanistic absorption simulation. AAPS Pharm Sci Tech. 2011;12:165-171.
22. Okumu A, Dimaso M, Lobenberg R. Computer simulations using GastroPlusTM to justify a biowaiver for etoricoxib solid oral drug products. Eur J Pharm Biopharm. 2009;72:91-98.
23. Wei H, Löbenberg R. Biorelevant dissolution media as a predictive tool for glyburide a class II drug. Eur J Pharm Sci. 2006;29:45-52.
24. Tang JL, Sun J, He ZG. Self-emulsifying drug delivery systems: strategy for improving oral delivery of poorly soluble drugs. Curr Drug Ther. 2007;2:85-93.
25. Luo M, Shen Q, Chen J. Transdermal delivery of paeonol using cubic gel and microemulsion gel. Int J Nanomedicine. 2011;6: 1603-1610.
26. Yang S, Gursoy RN, Lambert G, Benita S. Enhanced oral absorption of paclitaxel in a novel self-microemulsifying drug delivery system with or without concomitant use of P-glycoprotein inhibitors. Pharm Res. 2004;21:261-270.
27. Sharma G, Wilson K, Van der Walle CF, Sattar N, Petrie JR, Ravi Kumar MNV. Microemulsions for oral delivery of insulin: design, development and evaluation in streptozotocin induced diabetic rats. Eur J Pharm Biopharm. 2010;76:159-169.
28. Date AA, Nagarsenker MS. Parenteral microemulsions: an overview. Int J Pharm. 2008;355:19-30.
29. Gursoy N, Garrigue JS, Razafindratsita A, Lambert G, Benita S. Excipient effects on in vitro cytotoxicity of a novel paclitaxel self-emulsifying drug delivery system. J Pharm Sci. 2003;92:2411-2418.
30. Nornoo AO, Osborne DW, Chow DSL. Cremophor-free intravenous microemulsions for paclitaxel I: formulation, cytotoxicity and hemolysis. Int J Pharm. 2007;349:108-116.
31. Lam KW, Xu J, Ng KM. Pharmaceutical salt formation guided by phase diagrams. Ind Chem Res. 2010;49:12503-12512.
32. Yee S. In vitro permeability across Caco-2cells (colonic) can predict in vivo (small intestinal) absorption in man-fact or myth. Pharm Res. 1997;14:763-766.
33. Talegaonkar S, Azeem A, Ahmad FJ, Khar RK, Pathan SA, Khan ZI. Microemulsion: a novel approach to enhanced drug delivery. Recent Pat Drug Deliv Formul. 2008;2:238-257.
34. Kogan A, Garti N. Microemulsions as transdermal delivery vehicles. Adv Colloid Interface Sci. 2006;123-126:369-385.
35. Porter CJH, Trevaskis NL, Charman WN. Lipids and lipid-based formulations: optimizing the oral delivery of lipophilic drugs. Nat Rev Drug Discov. 2007;6:231-248.
36. Mirochnick M, Clarke DF, McNamara ER, Cabral H. Bioequivalence of a propylene glycol-based liquid dapsone preparation and dapsone tablets. Am J Health Syst Pharm. 2000;57:1775-1777.